Novo Nordisk's Downgraded Expectations - What The Market Is (Obviously) Missing

If you are interested in keeping up to date with stocks making moves within the biotech, pharma, and healthcare industries and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Novo Nordisk A/S ( NVO ) has previewed its Q2 sales and operating profit growth in a press release today and downgraded its full-year 2025 guidance also. At the time of writing, theThe group is for both novice and ...